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Diagnostic Problems in Huntington’s Chorea 
and Tardive Dyskinesia 
Martin Buxton 
W HEN THE CLINICIAN encounters a demented adult patient with choreiform movements he is likely to think of the diagnosis of Hun- 
tington’s chorea. However, when the family is inconclusive and the patient has 
been medicated with neuroleptic agents, the diagnosis of tardive dyskinesia, the 
late and frequently permanent complication of neuroleptics, must also be 
considered. How confidently can this differential diagnosis be made? An answer 
to this question will be sought by reviewing and comparing (1) the significant 
epidemiologic data, (2) the clinical descriptions, (3) the psychologic symp- 
tomatology, (4) associated drug use, (5) the speculated pathophysiologic 
mechanisms, (6) the presumptive pharmacologic diagnostic tests, (7) the neu- 
rochemical findings, (8) the radiographic and postmortem findings, and (9) other 
findings of both Huntington’s chorea and tardive dyskinesia. 
The following case history illustrates the difficulty that is sometimes en- 
countered when attempting to differentiate between Huntington’s chorea and tar- 
dive dyskinesia. 
A 40-year-old married Caucasian woman came to the emergency room complaining of increasing 
nervousness, inability to control her temper, and involuntary movements, all of which had become 
progressively worse over the preceding several years. 
The patient was one of four children; her 22- and 26-year-old brothers were asymptomatic. She did, 
however, have a 39-year-old brother who was described as being an alcoholic and who had had several 
hospitalizations for this problem. The patient’s mother was alive and well at age 60, but her father had 
died at age 67 at a nearby state psychiatric hospital. The father’s old hospital records revealed his 
having been diagnosed differently several times, e.g., character disorder, paranoid schizophrenic, 
chronic organic brain syndrome, and chronic undifferentiated schizophrenic. He had been treated for 
an unknown period of time with thioridazine 100 mg q.i.d. On one physical examination a few years 
before his death, he had been noted to be ataxic and to have a slight tremor. A postmortem exami- 
nation revealed left upper lobe pneumonia, advanced bilateral pulmonary emphysema, arte- 
riosclerotic heart disease, and fatty infiltration of the liver. Unfortunately, his cranium was not 
opened. The father was one of ten siblings; the others by history did not reveal any pathology, but four 
died accidental premature deaths, two had alcoholic problems, one died of an unspecified cancer, and 
two were reportedly well adjusted and in good health. 
During the clinical examination, the patient’s tongue protruded, she had a facial grimace. and her 
head rolled first to the side and then backward. At other times her upper limbs had the appearance of 
flying through the air, and her trunk would gyrate. She had a prancing steppage in her gait, but did not 
fall despite what appeared to be. poor balance while walking. Neuropsychiatric examination revealed 
her to be oriented to person and place, but she did not know the date. She made frequent errors in cal- 
culations and could not spell the word “world” backward. She was able to abstract from proverbs, 
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but demonstrated extreme denial of her movement disorder. Despite her severe dysarthria, she could 
repeat five numbers forward and three numbers backward. The patient complained of difficulty in her 
short-term memory, as she had been forgetting phone numbers and things on the stove. During the 
examination she wasn’t able to recall the name of three cities after 5 min. Cranial nerve testing was 
within normal limits except for failure to converge her vision and the absence of optokinetic nys- 
tagmus. Sensory examination showed decreased proprioception in all extremities. She made frequent 
errors in graphesthesia. Motor examination showed grossly choreiform movements as described 
above. She was able, however, to walk on her heels and toes. Cerebellar examination showed her 
finger-to-nose testing to be bilaterally abnormal.. Heel-to-shin testing was normal. Her ability to 
tandem-walk was poor, and rapid alternating movements were decreased, as were fine coordinated 
movements of the hands. Deep tendon reflexes were not increased; Babinski and Hoffman reflexes 
were absent. On physical examination her heart, lungs, and abdomen were nonremarkable. On history 
the patient claimed to have been taking Triavil4-25 mg q.i.d. intermittently for the previous 7 years, 
ever since she had become depressed and irritable. A pneumoencephalogram of the patient revealed 
slight cerebellar atrophy and complete absence of the caudate nucleus. The patient was diagnosed as 
having Huntington’s chorea and was treated with major tranquilizers. 
Thus, this 40-year-old female, who showed progressive deterioration in her 
ability to function and who manifested involuntary motor movements, was 
diagnosed as having Huntington’s chorea. But were her psychologic symptoms 
part of the presentation of this disease or were they nothing more than symptoms 
of depression and anxiety ? Were her involuntary movements part of the 
presentation of Huntington’s chorea or were they tardive dyskinesias secondary 
to her use of neuroleptic medications? Did her father have Huntington’s chorea 
or did he have some other disorder such as schizophrenia? 
EPIDEMIOLOGIC DATA 
George E. Crane, in his article “Persistent Dyskinesia,“’ states that the early 
findings and reviews of tardive dyskinesia reported it more likely to occur in fe- 
males, in the elderly, and in brain-damaged patients. He went on to point out, 
however, that there is some disagreement regarding these statements in the more 
recent literature. 
The studies by Degkwitz,2 Heinrich et a1.,3 Kennedy et a1.,4 Turunen and 
Achte,5 Villeneuve et a1.,0 Lehmann et al.,’ and Brandon et a1.8 have found fe- 
males to be more frequently affected, while studies by Crane,Q+*o Hippius and 
Lange,” and Fann et a1.12 have not found females more frequently affected. 
The variable of age is believed to be an important contributing factor in the de- 
velopment of tardive dyskinesia, but at least two authors do not regard it as such. 
Crane suggests that this discrepancy may be due to complex interactions between 
drug treatment and the characteristics of the population studied. As an example 
of this, he cites a study of his own on a selected sample of patients under 56 years 
of age in which he found that age was positively related to dyskinesia in only those 
receiving very high doses of trifluoperazine hydrochloride.‘O Another study by the 
same author mentioned below further substantiates age as a significant variable. 
Several authors have reported that preexisting brain damage and previous 
treatment with electroshock or insulin coma do not play a role in the de- 
velopment of tardive dyskinesia. *,12*13 However, Edwards,14 contradicting his own 
earlier findings,15 reported a highly significant difference between brain-damaged 
and non-brain-damaged patients in this respect. Crane“j reported a survey of 350 
patients from chronic hospital wards in whom he had attempted to relate the fre- 
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quency of tardive dyskinesia to age, sex, duration of continuous hospitalization, 
current treatment, and disorders of the central nervous system; he found that of 
these variables only age was positively related to dyskinesia at a high level of 
significance. 
Crane has also reported that the incidence of tardive dyskinesia varies from 
0.5% to 40% in the populations surveyed by 17 investigators.’ He attributed this 
variance to a number of factors: the methods used in obtaining information, the 
definition of the syndrome, the type of patient population studied, and most 
significantly the differences in clinical assessment of symptoms. 
Reviewing the epidemiology of Huntington’s chorea, most studies agree that 
the prevalence of this disease ranges from 4 to 7 per 100,000 population.17 The 
early notion that Huntington’s chorea is virtually absent among Jews is no longer 
substantiated, as Myrianthopoulos found the prevalence among Jews to be at 
least 1 in 28,000.17 This disease is found with varying prevalence in various parts 
of the world.‘8 
Epidemiologic comparisons with schizophrenia, the illness that is most likely 
to require the use of neuroleptics, reveals some intriguing data. In both Hun- 
tington’s chorea and schizophrenia the risk of onset is minimal after the age of 
55, and the earlier the onset the poorer the prognosis.1g A genetic cause and a 
monogenic, autosomal-dominant mode of transmission seem to be established in 
Huntington’s chorea,lg while an increased risk for schizophrenia among the 
offspring of schizophrenics has also been established.20 The importance of a 
conclusive family history in making the diagnosis of Huntington’s chorea is re- 
flected by the paucity of reported cases of choreics born to nonchoreic parents.” 
CLINICAL DESCRIPTIONS 
According to a special report by the American College of Neuropsycho- 
pharmacology-Food and Drug Administration Task Force,22 the “bucco-linguo- 
masticatory” (BLM) triad are the most frequently described symptoms of tar- 
dive dyskinesia. This triad consists of sucking and smacking movements of the 
lips, lateral jaw movements, and tongue movements described as thrust, roll, or 
fly-catching. A chewing-the-cud type of movement can be seen when the mouth is 
kept closed and the tongue thereby hits the side of the cheek. Other modes of 
onset besides the BLM syndrome can be found, e.g., tic-like movements of the 
lips and eyes. As is also the case in Huntington’s chorea, the oral and other move- 
ments may worsen under emotional stress and will disappear during sleep. 
Significant to the scope of this paper is the finding that the extremities of patients 
with tardive dyskinesias sometimes show choreiform movements. These are 
variable, purposeless, and involuntary quick movements that frequently increase 
with attention. Other authors have described the fingers as exhibiting a guitar- 
playing movement. 23 When the abnormal motility of the fingers or toes becomes 
rhythmical, a tremor-like movement can be seen if the hand or foot is rested on a 
firm surface. The feet and ankles are also affected at times, and as they rotate in 
all directions they sometimes assume an equinovarus position. Thigh movements, 
alternating adduction and abduction, often accompany movements in the distal 
portions of the lower extremities. Abnormal diaphragmatic motility can cause 
respiratory dyskinesia. 23 Infrequently, the spine may demonstrate a to-and-fro 
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clonic movement in the anteroposterior direction.22 Thus the movements found in 
tardive dyskinesia span the whole body and can include one or many of the same 
movements usually associated with Huntington’s chorea. 
The similarity described above is highlighted by Klawans’ statement that 
“patients with Huntington’s chorea often present with movements that are 
similar in appearance to tardive dyskinesias.“24 Furthermore, there is 
considerable variation in the movement disorders of patients with Huntington’s 
chorea. An appreciation of this variation can be gained by reviewing the literature 
of this disorder and noting the different forms or types that have been described 
on the basis of clinical presentation. A rigid and akinetic or juvenile type, a status 
subchoreaticus type, a chorea Huntington sine chorea type, and a hyperkinetic 
hypotonic adult type have all been described. 25 The variation in movement disor- 
ders in Huntington’s chorea can also be appreciated in the new classification 
scheme suggested by Stevens in his tabular summary of the various clinical cate- 
gories of patients with Huntington’s chorea. 
PSYCHOLOGIC SYMPTOMS 
Disordered behavior, and in its extreme, dementia, are readily associated with 
the clinical course of Huntington’s chorea. However, three different sets of 
disordered behavior have been described either coincident with or following the 
appearance of the chorea. I9 The first set is composed of behavior that is at- 
tributable to a dementia and includes impaired memory, impaired concentration, 
impaired orientation, and confusion. The second set consists of aberrant forms of 
behavior that are nonspecific but that involve a lesser deterioration of the brain. 
Included in this set are emotional lability, euphoria or depression, restlessness or 
apathy, irritability, and self-neglect. The third set consists of behavior that is 
similar to the behavior found in schizophrenia. Included are inappropriate sexual 
behavior, preoccupation with the imputed sexual misbehavior of others, delu- 
sional persecutory beliefs, delusions of grandeur, and apparent hallucinations. 
Behavior of this third set often leads to a primary diagnosis of mania, psychotic 
depression, or paranoid schizophrenia. lg However, even when the choreic move- 
ments are present, a diagnosis of schizophrenia could be made by regarding these 
symptoms as stereotypic behavior or tics or, as pertinent to this paper, 
schizophrenia with tardive dyskinesia. Furthermore, episodes of hallucinatory 
and paranoid assaultive behavior have been frequently reported in patients with 
Huntington’s chorea.lg Significantly, there does not appear to be a pattern or 
even an often repeated time relationship between the onset of the chorea and psy- 
chosis, and therefore it is possible in the early stages to misdiagnose an organic 
disorder as a functional disorder. I9 If the contention of these authors that Hun- 
tington’s chorea can have a schizophrenic appearance, a schizophrenic onset, or 
even be accompanied by schizophrenia is true, the psychologic presentation of the 
patient may at times be of little help in differentiating between these disorders. 
ASSOCIATED DRUG USE 
“The high incidence of involuntary movements in drug-treated populations, 
and the relative rarity of such abnormalities in similar untreated populations 
provide compelling evidence to indicate that tardive dyskinesia is related to the 
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use of phenothiazines or similar agents.“’ According to Ayd,26 the earliest onset 
of tardive dyskinesia was between 3 and 6 months after the beginning of drug 
therapy. While two &her studies 5.27 have also found dyskinesias in patients who 
had been on neuroleptics for 4 and 6 months, the majority of patients with dyski- 
nesias have been on these drugs for over 2 years.’ This question about duration of 
drug use and onset of tardive dyskinesia is further complicated by the belief that 
some patients can actually have the disorder before it is recognized, as it is 
believed that the disorder can be masked while the patient is still taking the 
medication. * 
Further evidence to support the contention that the differential diagnosis be- 
tween Huntington’s chorea and tardive dyskinesia can be difficult is provided by 
Ringel et a1.28 According to their survey, the majority of Huntington’s patients 
are being treated with neuroleptic medications. Of the 306 patients surveyed, 192 
were being medicated with neuroleptics. Haloperidol and chlorpromazine were 
most commonly used for these Huntington’s chorea patients. These drugs are 
also widely prescribed for the general psychiatric population and have been impli- 
cated in cases that later developed tardive dyskinesia.2g 
PATHOPHYSIOLOGIC MECHANISMS 
The widely held pathophysiologic hypotheses for both Huntington’s chorea and 
tardive dyskinesias are based on the belief that certain dopaminergic receptors in 
the striatum have become hypersensitive. In tardive dyskinesias the pathophysio- 
logic mechanism is believed to be similar to a chemical denervation hyper- 
sensitivity of the dopaminergic nerve endings following prolonged receptor 
blockade by neuroleptics. 3o In Huntington’s chorea the hypersensitivity is 
believed to be the result of the degenerative process of the disease.31 Is it possible 
that when one treats a Huntington’s chorea patient with neuroleptics one is 
actually exacerbating the preexisting hypersensitivity or causing a tardive dyski- 
nesia in addition to the already present hereditary chorea? This question should 
be paramount even though there is no alternative at the present time to the pallia- 
tive treatment with neuroleptics. 
PRESUMPTIVE PHARMACOLOGIC DIAGNOSTIC TESTS 
Despite some recent interesting findings in this area, there is still no presump- 
tive pharmacologic diagnostic test to differentiate between Huntington’s chorea 
and tardive dyskinesia. Interestingly, most agents that either improve or exacer- 
bate one disorder also have the same effect on the other. For example, L-dopa, 
which is presently being tried as a diagnostic agent in asymptomatic individuals at 
risk for Huntington’s chorea, 32 has been shown to exacerbate the movement 
disorders in both Huntington’s chorea and tardive dyskinesia.2g Furthermore, 
there are reports in the literature indicating that a drug holiday exacerbates the 
movements in tardive dyskinesia, while the resumption of neuroleptics at the 
same dose level or a sudden increase in dose will cause a temporary improve- 
ment.30 These same phenomena have been standard clinical observations in Hun- 
tington’s chorea. Another recent observation that has caused a great deal of in- 
terest involves the use of a Gaba analogue. The early results with Gaba indicate 
that Huntington’s patients can tolerate the analogue at moderate doses, while 
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control subjects cannot. 33 It is not known as yet how tardive dyskinesia patients 
would respond to the Gaba analogue or even if they have low Gaba levels (see the 
discussion below on Gaba levels in Huntington’s chorea). Physostigmine 
salicylate has been shown to cause some alleviation of symptoms in Huntington’s 
chorea, and anticholinergic medications have caused exacerbations of 
symptoms in both. 24 Recently there have been preliminary reports in the 
literature as to apomorphine’s effectiveness in the treatment of acutely induced 
neuroleptic dyskinesias, 34 tardive dyskinesias, and Huntington’s chorea. Thus 
the results of various trials with pharmacologic agents have furthered the belief 
that there are similar mechanisms involved in both Huntington’s chorea and tar- 
dive dyskinesias and have not advanced our ability to differentiate these two 
disorders. 
NEUROCHEMICAL FINDINGS 
As mentioned above, the Gaba findings in Huntington’s chorea have generated 
a great deal of interest. Gaba or y-aminobutyric acid is a proposed neurotrans- 
mitter that has been shown to be released from mammalian brain surfaces during 
inhibitory activity or after stimulation of subcortical regions.33 Gaba levels in the 
extrapyramidal system of patients with Huntington’s chorea have been shown to 
be reduced significantly. 31 Gaba levels in patients with tardive dyskinesia have yet 
to be investigated. 
Early reports in the literature indicated that CSF homovanillic acid (HVA) 
concentrations were within normal limits in tardive dyskinesia24 and were normal 
or slightly decreased in Huntington’s chorea. However, “more detailed recent 
regional determinations . . . now indicate that caudate dopamine and HVA 
cncentrations are significantly decreased” in Huntington’s chorea. Patients 
with this disorder at postmortem also had “markedly less average choline 
acetylase activity in the caudate and putamen” than did a normal group of con- 
trols. Furthermore, brains from Huntington’s chorea patients have had relatively 
reduced GAD (glutamic acid decarboxylase), the enzyme responsible for Gaba 
synthesis and reduced activities in the caudate, putamen, globus pallidus, and 
substantia nigra, while the tyrosine hydroxylase concentration was not found to 
be reduced.31 The values of choline acetylase, GAD, and tyrosine hydroxylase in 
brain of tardive dyskinesia patients are not known. The serum ceruloplasmin 
values in patients with Huntington’s chorea have been reported to be low,33 while 
again the value of this chemistry in dyskinesias is not known. 
RADIOGRAPHIC AND POSTMORTEM FINDINGS 
Blinderman et al., reporting in 1964 on the pneumoencephalograms of eight 
patients with Huntington’s chorea, stated that the radiographic appearance 
varied from being normal to showing characteristic atrophy of the caudate and 
putamen. They found that there was no clinical correlation of severity or du- 
ration of the illness with the radiographic appearance and concluded that the 
presence of a normal pneumoencephalogram does not rule out a diagnosis of 
Huntington’s chorea. However, Gath and Vinje,37 reporting in 1968 on a Hun- 
tington’s chorea patient population of 36, found an increased width of the ven- 
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tricular bodies in the majority of cases, while the frontal horns did not appear 
specifically enlarged. Furthermore, “although no clear correlation was found be- 
tween the degree of the radiologic findings and the severity of clinical symptoms, 
all of the patients with severe mental changes were found to have severe enlarge- 
ment of the ventricular body.“37 A postmortem study by Christensen et a1.3R 
revealed that 3 brains (out of 28) from patients who had dyskinesias before their 
deaths and 3 brains from controls without dyskinesias before their deaths (also 
out of 28) demonstrated encephalomalacic processes in the caudate nuclei and 
that 18 of the dyskinetic and 14 of the control brains demonstrated gliosis in the 
caudate nuclei. What would the pneumoencephalograms of these dyskinetic 
patients have looked like? Might there not have been the appearance of enlarged 
ventricular bodies secondary to the atrophy of the caudates? Young and 
Crampton found that 24 of their sample of 36 schizophrenic patients had clear ce- 
rebral atrophy and that “the incidence of atrophy in middle-aged hospitalized 
patients was as high as that found in neurological patients in whom atrophy had 
been expected.“3g As yet there has been no reported study of the pneumoen- 
cephalographic findings in tardive dyskinesia. 
At present it is unclear if the CAT (computerized axial tomography scan) find- 
ings in Huntington’s chorea and tardive dyskinesia will be helpful in distinguishing 
one disorder from the other. 
OTHER FINDINGS 
One interesting finding is that in both Huntington’s chorea and tardive dyski- 
nesia there is an impairment of the optokinetic nystagmus.40 It has also been 
reported that Huntington’s chorea patients have an inability to make rapid eye 
movements in all oculomotor activities ranging from voluntary to reflexively 
elicited movementszg Disturbances of ocular motility in tardive dyskinesia 
patients, other than optokinetic reflexes, have not been reported. 
CONCLUSION 
The diagnosis of Huntington’s chorea is clear in cases with positive family his- 
tory for the disorder and a progressive deterioration of the patient marked by 
choreiform movements and psychologic symptoms resulting in dementia. Simi- 
larly, the diagnosis of tardive dyskinesia is clear in cases where there is no family 
history of Huntington’s chorea and where the patient had been using neuroleptics 
before developing dyskinesias. Unfortunately, many cases fall within the con- 
tinuum between these two clear-cut clinical pictures. It is in this area that caution 
must be exercised to avoid the pitfalls of a hasty diagnosis, as there are numerous 
similarities between these two disorders. It is concluded that in many cases a 
definitie diagnosis may not be possible. Further work in the areas of comparative 
neurochemistries, neuropathology, neuropharmacology, and pneumoencephalog- 
raphy will be necessary in order to make this differential diagnosis more easily. 
Finally, the author submits the disconcerting possibility that Huntington’s 
chorea patients treated with neuroleptics may be especially prone to develop tar- 
dive dyskinesia in addition to their already present hereditary choreas. 
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